New-onset third-degree atrioventricular block because of autoimmune-induced myositis under treatment with anti-programmed cell death-1 (nivolumab) for metastatic melanoma
Juliane Behling, Joachim Kaes, Thomas F. Münzel et al. · Melanoma Research · 2016
There has been considerable progress in treating malignant melanoma over the last few years. The immune-checkpoint-inhibitors nivolumab and pembrolizumab have been approved by the Food and Drug Administration in 2014 for the therapy of metastatic melanoma. Anti-programmed cell death-1-blocking antibodies are known to cause immune-related adverse events. Physicians should be aware of common and rare side effects and pay attention to new ones. We therefore report a severe and life-threatening side effect of anti-programmed cell death-1 immunotherapy with nivolumab that has not been previously reported: the development of a third-degree atrioventricular block. After a second infusion with nivolumab, our patient developed a troponin I-positive and autoantibody-positive myositis and a few days later a new-onset third-degree atrioventricular block. This is most likely because of an autoimmune-induced myositis with a cardiac impairment in terms of a myocarditis, which led to an impairment of the conduction of cardiac electrical stimuli.
Cited by 132 works. doi:10.1097/cmr.0000000000000314
Authors
References
- Recommendations for Cardiac Chamber Quantification by Echocardiography in Adults: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging
- Nivolumab plus Ipilimumab in Advanced Melanoma
- Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies
- Managing Immune Checkpoint-Blocking Antibody Side Effects
- Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy
- Acute heart failure due to autoimmune myocarditis under pembrolizumab treatment for metastatic melanoma
- Echocardiographic findings in fulminant and acute myocarditis
- Echocardiographic reference ranges for normal cardiac chamber size: results from the NORRE study
- PD-1 Blockers
- Myocarditis as an immune-related adverse event with ipilimumab/nivolumab combination therapy for metastatic melanoma